[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549157":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":28,"locations":39,"responsibleParty":58,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 - DP",null,"Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine",[13],"Diagnostic Test: urine and blood test",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 - Trientine","Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3 - ZINC","Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","urine and blood test","3 urine collections of an 8h period. One blood sample for liver function test and copper assessment",[9,15,19],[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Eduardo COUCHONNAL, Dr","CONTACT","04 27 35 70 50","+33","eduardo.couchonnal-bedoya@chu-lyon.fr",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Abdelouahed BELMALIH, PhD","04 27 85 62 67","abdelouahed.belmalih@chu-lyon.fr",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Service de Gastroentérologie, Hépatologie et Nutrition Pédiatriques - Hôpital Femme Mère Enfant","RECRUITING","Bron","Rhone","69500","France","FR",{"type":49,"coordinates":50},"Point",[51,52],4.91303,45.73865,{"lat":52,"lon":51},[55,57],{"name":56,"role":31,"phone":32,"phoneExt":33,"email":34},"Eduardo Couchonnal, Dr",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100549157","circadian-variation-of-urinary-copper-excretion-in-wilson-disease-patients-100549157",false,"NCT06430359","Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients","Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients Treated With Chelators or Zinc Salts","VARCUWIC","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4).\n* Age ≥ 6 years and ≤70 years.\n* Patient able to perform 24h urine.\n* Current treatment with D-Pencillamine, Trientine or Zinc.\n* Non-opposition of patient and\u002For legal representatives for minor patients.\n\nExclusion Criteria:\n\n* Patients who had a change in treatment within the last 6 months before the inclusion\n* Patients who have undergone liver transplantation\n* Patients with known chronic renal failure (GFR \\\u003C 30 ml\u002Fmin)\n* Patients on long-term diuretic or corticosteroid therapy\n* Persons deprived of liberty by a judicial or administrative decision\n* Patient under judicial protection, unable to express consent","ALL","6 Years","70 Years",{"count":72,"type":73},30,"ESTIMATED","OBSERVATIONAL","Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.\n\nTreatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.\n\nMonitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.\n\nNevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.\n\nThere is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.\n\nAccording to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.\n\nThe study would aim to find the period of the day best correlated with 24h urinary copper excretion",[77],"Wilson Disease",[79,80,81],"Wilson disease","urinary copper","chelator","2026-01-13",{"date":84,"type":85},"2026-01-15","ACTUAL",{"date":87,"type":85},"2025-01-10",{"date":89,"type":73},"2027-02-10",{"name":5,"class":6},1]